Top

Published in:

01-07-2011 | Original article

A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells

Authors: Chi-Chen Lin, Yen-Ling Yu, Chia-Chiao Shih, Ko-Jiunn Liu, Keng-Liang Ou, Ling-Zong Hong, Jody D. C. Chen, Ching-Liang Chu

Published in: Cancer Immunology, Immunotherapy | Issue 7/2011

Abstract

DNA vaccine has been suggested to use in cancer therapy, but the efficacy remains to be improved. The immunostimulatory effect of a fungal immunomodulatory protein Ling Zhi-8 (LZ-8) isolated from Ganoderma lucidum has been reported. In this study, we tested the adjuvanticity of LZ-8 for HER-2/neu DNA vaccine against p185^neu expressing tumor MBT-2 in mice. We found that recombinant LZ-8 stimulated mouse bone marrow-derived dendritic cells (DCs) via TLR4 and its stimulatory effect was not due to any microbe contaminant. In addition, LZ-8 enhanced the ability of DCs to induce antigen-specific T cell activation in vitro and in a subunit vaccine model in vivo. Surprisingly, LZ-8 cotreatment strongly improved the therapeutic effect of DNA vaccine against MBT-2 tumor in mice. This increase in antitumor activity was attributed to the enhancement of vaccine-induced Th1 and CTL responses. Consistent with the results from DCs, the promoting effect of LZ-8 on DNA vaccine was diminished when the MBT-2 tumor cells were grown in TLR4 mutant mice. Thus, we concluded that LZ-8 may be a promising adjuvant to enhance the efficacy of DNA vaccine by activating DCs via TLR4.

Available only for authorised users

Rice J, Ottensmeier CH, Stevenson FK (2005) DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8:108–120CrossRef

Liu MA (2010) Gene-based vaccines: recent developments. Curr Opin Mol Ther 12:86–93 ReviewPubMed

Cai Y, Rodriguez S, Hebel H (2009) DNA vaccine manufacture: scale and quality. Expert Rev Vaccines 8:1277–1291PubMedCrossRef

Loisel-Meyer S, Foley R, Medin JA (2008) Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Front Biosci 13:3202–3214PubMedCrossRef

Bodles-Brakhop AM, Draghia-Akli R (2008) DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert Rev Vaccines 7:1085–1101PubMedCrossRef

Signori E, Iurescia S, Massi E, Fioretti D, Chiarella P, De Robertis M, Rinaldi M, Tonon G, Fazio VM (2010) DNA vaccination strategies for anti-tumour effective gene therapy protocols. Cancer Immunol Immunother 59:1583–1591PubMedCrossRef

Fioretti D, Iurescia S, Fazio VM, Rinaldi M (2010) DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010:174378PubMedCrossRef

Banchereau J, Klechevsky E, Schmitt N, Morita R, Palucka K, Ueno H (2009) Harnessing human dendritic cell subsets to design novel vaccines. Ann N Y Acad Sci 1174:24–32PubMedCrossRef

Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140:805–820PubMedCrossRef

10.

Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7:790–802PubMedCrossRef

11.

Hubbell JA, Thomas SN, Swartz MA (2009) Materials engineering for immunomodulation. Nature 462:449–460PubMedCrossRef

12.

Boh B, Berovic M, Zhang J, Zhi-Bin L (2007) Ganoderma lucidum and its pharmaceutically active compounds. Biotechnol Annu Rev 13:265–301PubMedCrossRef

13.

Sanodiya BS, Thakur GS, Baghel RK, Prasad GB, Bisen PS (2009) Ganoderma lucidum: a potent pharmacological macrofungus. Curr Pharm Biotechnol 10:717–742PubMedCrossRef

14.

Kino K, Yamashita A, Yamaoka K, Watanabe J, Tanaka S, Ko K, Shimizu K, Tsunoo H (1989) Isolation and characterization of a new immunomodulatory protein, ling zhi-8 (LZ-8), from Ganoderma lucidium. J Biol Chem 264:472–478PubMed

15.

Lin WH, Hung CH, Hsu CI, Lin JY (1997) Dimerization of the N-terminal amphipathic alpha-helix domain of the fungal immunomodulatory protein from Ganoderma tsugae (Fip-gts) defined by a yeast two-hybrid system and site-directed mutagenesis. J Biol Chem 272:20044–20048PubMedCrossRef

16.

Hsu HC, Hsu CI, Lin RH, Kao CL, Lin JY (1997) Fip-vvo, a new fungal immunomodulatory protein isolated from Volvariella volvacea. Biochem J 323(Pt 2):557–565PubMed

17.

Li Q, Wang X, Chen Y, Lin J, Zhou X (2010) Cytokines expression induced by Ganoderma sinensis fungal immunomodulatory proteins (FIP-gsi) in mouse spleen cells. Appl Biochem Biotechnol 162:1403–1413PubMedCrossRef

18.

van der Hem LG, van der Vliet JA, Kino K, Hoitsma AJ, Tax WJ (1996) Ling-Zhi-8: a fungal protein with immunomodulatory effects. Transplant Proc 28:958–959PubMed

19.

Hsu HY, Hua KF, Wu WC, Hsu J, Weng ST, Lin TL, Liu CY, Hseu RS, Huang CT (2008) Reishi immuno-modulation protein induces interleukin-2 expression via protein kinase-dependent signaling pathways within human T cells. J Cell Physiol 215:15–26PubMedCrossRef

20.

Lin YL, Liang YC, Tseng YS, Huang HY, Chou SY, Hseu RS, Huang CT, Chiang BL (2009) An immunomodulatory protein, Ling Zhi-8, induced activation and maturation of human monocyte-derived dendritic cells by the NF-kappaB and MAPK pathways. J Leukoc Biol 86:877–889PubMedCrossRef

21.

Lin CC, Chou CW, Shiau AL, Tu CF, Ko TM, Chen YL, Yang BC, Tao MH, Lai MD (2004) Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 10:290–301PubMedCrossRef

22.

Chu CL, Lowell CA (2005) The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation. J Immunol 175:2880–2889PubMed

23.

Chu CL, Yu YL, Shen KY, Lowell CA, Lanier LL, Hamerman JA (2008) Increased TLR responses in dendritic cells lacking the ITAM-containing adapters DAP12 and FcRgamma. Eur J Immunol 38:166–173PubMedCrossRef

24.

Huang RY, Yu YL, Cheng WC, Ouyang CN, Fu E, Chu CL (2010) Immunosuppressive effect of quercetin on dendritic cell activation and function. J Immunol 184:6815–6821PubMedCrossRef

25.

Lin CC, Tu CF, Yen MC, Chen MC, Hsieh WJ, Chang WC, Chang WT, Lai MD (2007) Inhibitor of heat-shock protein 90 enhances the antitumor effect of DNA vaccine targeting clients of heat-shock protein. Mol Ther 15:404–410PubMedCrossRef

26.

Yu YL, Chen IH, Shen KY, Huang RY, Wang WR, Chou CJ, Chang TT, Chu CL (2009) A triterpenoid methyl antcinate K isolated from Antrodia cinnamomea promotes dendritic cell activation and Th2 differentiation. Eur J Immunol 39:2482–2491PubMedCrossRef

27.

Lai MD, Chen CS, Yang CR, Yuan SY, Tsai JJ, Tu CF, Wang CC, Yen MC, Lin CC (2010) An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine. Cancer Gene Ther 17:203–211PubMedCrossRef

28.

Lin CC, Yen MC, Lin CM, Huang SS, Yang HJ, Chow NH, Lai MD (2008) Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer. J Gene Med 10:679–689PubMedCrossRef

29.

Tu CF, Lin CC, Chen MC, Ko TM, Lin CM, Wang YC, Lai MD (2007) Autologous neu DNA vaccine can be as effective as xenogenic neu DNA vaccine by altering administration route. Vaccine 25:719–728PubMedCrossRef

30.

Yen MC, Lin CC, Chen YL, Huang SS, Yang HJ, Chang CP, Lei HY, Lai MD (2009) A novel cancer therapy by skin delivery of indoleamine 2, 3-dioxygenase siRNA. Clin Cancer Res 15:641–649PubMedCrossRef

31.

Huang CH, Chang CC, Lin CM, Wang ST, Wu MT, Li EI, Chang HC, Lin CC (2010) Promoting effect of Antrodia camphorata as an immunomodulating adjuvant on the antitumor efficacy of HER-2/neu DNA vaccine. Cancer Immunol Immunother 59:1259–1272PubMedCrossRef

32.

Lai MD, Yen MC, Lin CM, Tu CF, Wang CC, Lin PS, Yang HJ, Lin CC (2009) The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model. Genet Vaccines Ther 7:2PubMedCrossRef

33.

Bolhassani A, Rafati S (2008) Heat-shock proteins as powerful weapons in vaccine development. Expert Rev Vaccines 7:1185–1199PubMedCrossRef

34.

Chen T, Guo J, Han C, Yang M, Cao X (2009) Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol 182:1449–1459PubMed

35.

Mossman KL, Mian MF, Lauzon NM, Gyles CL, Lichty B, Mackenzie R, Gill N, Ashkar AA (2008) Cutting edge: FimH adhesin of type 1 fimbriae is a novel TLR4 ligand. J Immunol 181:6702–6706PubMed

36.

Kono H, Rock KL (2008) How dying cells alert the immune system to danger. Nat Rev Immunol 8:279–289PubMedCrossRef

37.

Marincek BC, Kuhnle MC, Srokowski C, Schild H, Hammerling G, Momburg F (2008) Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion. Mol Immunol 46:181–191PubMedCrossRef

38.

Tsan MF, Baochong G (2007) Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors. J Endotoxin Res 13:6–14PubMedCrossRef

39.

Tong MH, Chien PJ, Chang HH, Tsai MJ, Sheu F (2008) High processing tolerances of immunomodulatory proteins in Enoki and Reishi mushrooms. J Agric Food Chem 56:3160–3166PubMedCrossRef

40.

Yeh CH, Chen HC, Yang JJ, Chuang WI, Sheu F (2010) Polysaccharides PS-G and protein LZ-8 from Reishi (Ganoderma lucidum) exhibit diverse functions in regulating murine macrophages and T lymphocytes. J Agric Food Chem 58:8535–8544PubMedCrossRef

41.

Huang L, Sun F, Liang C, He YX, Bao R, Liu L, Zhou CZ (2009) Crystal structure of LZ-8 from the medicinal fungus Ganoderma lucidium. Proteins 75:524–527PubMedCrossRef

42.

Jin MS, Lee JO (2008) Structures of the toll-like receptor family and its ligand complexes. Immunity 29:182–191PubMedCrossRef

43.

Hsu TL, Cheng SC, Yang WB, Chin SW, Chen BH, Huang MT, Hsieh SL, Wong CH (2009) Profiling carbohydrate-receptor interaction with recombinant innate immunity receptor-Fc fusion proteins. J Biol Chem 284:34479–34489PubMedCrossRef

44.

Paaventhan P, Joseph JS, Seow SV, Vaday S, Robinson H, Chua KY, Kolatkar PR (2003) A 1.7A structure of Fve, a member of the new fungal immunomodulatory protein family. J Mol Biol 332:461–470PubMedCrossRef

45.

Ding Y, Seow SV, Huang CH, Liew LM, Lim YC, Kuo IC, Chua KY (2009) Coadministration of the fungal immunomodulatory protein FIP-Fve and a tumour-associated antigen enhanced antitumour immunity. Immunology 128:e881–e894PubMedCrossRef

46.

Sheu F, Chien PJ, Hsieh KY, Chin KL, Huang WT, Tsao CY, Chen YF, Cheng HC, Chang HH (2009) Purification, Cloning, and Functional Characterization of a Novel Immunomodulatory Protein from Antrodia camphorata (Bitter Mushroom) That Exhibits TLR2-Dependent NF-kappaB Activation and M1 Polarization within Murine Macrophages. J Agric Food Chem 57:4130–4141PubMedCrossRef

47.

Jinn TR, Wu CM, Tu WC, Ko JL, Tzen JT (2006) Functional expression of FIP-gts, a fungal immunomodulatory protein from Ganoderma tsugae in Sf21 insect cells. Biosci Biotechnol Biochem 70:2627–2634PubMedCrossRef

48.

Yeh CM, Yeh CK, Hsu XY, Luo QM, Lin MY (2008) Extracellular expression of a functional recombinant Ganoderma lucidium immunomodulatory protein by Bacillus subtilis and Lactococcus lactis. Appl Environ Microbiol 74:1039–1049PubMedCrossRef

49.

Xue Q, Ding Y, Shang C, Jiang C, Zhao M (2008) Functional expression of LZ-8, a fungal immunomodulatory protein from Ganoderma lucidium in Pichia pastoris. J Gen Appl Microbiol 54:393–398PubMedCrossRef

50.

Granucci F, Zanoni I, Pavelka N, Van Dommelen SL, Andoniou CE, Belardelli F, Degli Esposti MA, Ricciardi-Castagnoli P (2004) A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med 200:287–295PubMedCrossRef

51.

Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29:372–383PubMedCrossRef

52.

Ladjemi MZ, Jacot W, Chardes T, Pelegrin A, Navarro-Teulon I (2010) Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 59:1295–1312PubMedCrossRef

53.

Sheng WY, Huang L (2011) Cancer Immunotherapy and Nanomedicine. Pharm Res 28:200–214PubMedCrossRef

Title: A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells
Authors: Chi-Chen Lin
Yen-Ling Yu
Chia-Chiao Shih
Ko-Jiunn Liu
Keng-Liang Ou
Ling-Zong Hong
Jody D. C. Chen
Ching-Liang Chu
Publication date: 01-07-2011
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 7/2011
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-011-1016-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2011

Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas

B7-H4 expression associates with cancer progression and predicts patient’s survival in human esophageal squamous cell carcinoma

Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer

Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination

Tumor-derived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

Keynote webinar | Spotlight on antibody–drug conjugates in cancer